This work showed that anlotinib plus icotinib could achieve promising ORR and PFS in patients with concomitant mutations. Although first line osimertinib may bring better PFS, patients harboring concurrent mutations such as TP53 still have shorter PFS than reported in the present trial [36,37,38]....
Meaning Ivonescimab plus chemotherapy significantly improved progression-free survival with tolerable safety profile in patients with non–small cell lung cancer who previously underwent EGFR-TKI treatment and may offer a new treatment option for patients with TKI resistance. Abstract Importance For patient...
Meaning Combination therapy with osimertinib and bevacizumab met its primary end point for effectiveness, and a randomized phase 3 trial of osimertinib vs osimertinib and bevacizumab is moving forward. Abstract Importance The combination of erlotinib and bevacizumab as initial treatment of epidermal growth...
In SCLC, high serum visfatin levels are associated with brain metastases and visfatin appears to promote SCLC cell migration across the blood–brain barrier [22]. A recently developed dual inhibitor of visfatin and EGFR has shown excellent antiproliferative activities in various cancer cell lines, ...
CtDNA testing may be used to detect mutations that make the tumor sensitive to targeted therapy (sensitizing mutations). However, ctDNA testing is known to sometimes give false-negative results (meaning the mutation is present but not detected by the ctDNA testing). For this reason, the FDA ...
“Often, patients with EGFR-mutated NSCLC develop resistance to treatment during the course of therapy. Resistance in patients is typically diverse and polyclonal, meaning their tumors can have more than one type of resistance caused by different pathways. These variables can make their ...
(Qiagen, Hilden, Germany) according to the blood and body fluid spin protocol in the manufacturer's instructions, with the following protocol modifications. The same column was used repeatedly until the whole sample had been processed. The DNA obtained was eluted in 50 μl of sterile bi-...
The T790M mutation is selective, meaning it is a drug-resistant clone that survived TKI treatment. Prior to TKI treatment, the wild type version and the drug-resistant version of the same mutation both possibly exist. However, when selective pressure is applied on these alleles, the drug-resist...
(Figure 2a) after circ_CHFR silencing, meaning that the interfering plasmid of circ_CHFR was successfully built. Subsequently, data disclosed that cell cycle arrested at G0/G1 phase after ox-LDL treatment in HBMECs, whereas this effect was attenuated by circ_CHFR silencing (Figure 2b). The ...
Meaning Ivonescimab plus chemotherapy significantly improved progression-free survival with tolerable safety profile in patients with non–small cell lung cancer who previously underwent EGFR-TKI treatment and may offer a new treatment option for patients with TKI resistance. Abstract Importance For pat...